Does stem cell therapy cure cerebral palsy?
No. Stem cell therapy does not cure cerebral palsy (CP), and no treatment currently available can reverse the brain injury that causes it. CP results from damage to the developing brain before, during or shortly after birth, and that damage is permanent.

What research shows is that some cell therapies, including umbilical cord mesenchymal stem cells (MSCs), may improve motor function and daily activities in some children when combined with rehabilitation. A randomized, double-blind, placebo-controlled trial of intravenous (IV) umbilical cord MSCs in children with CP and a meta-analysis of randomized trials both reported measurable gains, with results that vary between patients. At Stem Cell Mexico, CP protocols use only allogeneic MSCs from Wharton's jelly of the umbilical cord, as a supportive treatment that complements physical, occupational and speech therapy. The goal is to support function and quality of life, not to cure the condition.
This guide explains why CP cannot be cured, what cell therapy may realistically contribute and how families can set goals that make sense for their child or for an adult living with CP.
What cerebral palsy is
Cerebral palsy is a group of disorders that affect movement, muscle tone and posture. It is the most common motor disability in childhood. According to the U.S. Centers for Disease Control and Prevention (CDC), CP is caused by abnormal development of, or damage to, the parts of the brain that control movement, balance and posture.
Common causes and risk factors include:
- Premature birth and low birth weight.
- Lack of oxygen or blood flow to the brain around birth (hypoxic-ischemic injury).
- Bleeding in the brain in premature babies.
- Infections during pregnancy or in early infancy.
- Stroke before or shortly after birth.
- Genetic and developmental factors in some cases.
CP is classified by the type of movement problem (spastic, dyskinetic, ataxic or mixed) and by the parts of the body affected. The Gross Motor Function Classification System (GMFCS) describes severity from level I (walks without limitations) to level V (needs a wheelchair and significant support).
Many people with CP also have associated conditions, such as epilepsy, intellectual disability, vision or hearing problems, swallowing difficulties, speech disorders and orthopedic complications like hip displacement and scoliosis.
Why a cure is not possible today
The brain injury in CP happens at a single point in early life and does not get worse over time. However, the injured brain tissue does not regenerate. Neurons and connections that were lost are not replaced, and no current therapy, including cell therapy, can rebuild them.
What does change over time is how the person's body and brain adapt. The developing brain has considerable neuroplasticity, especially in early childhood, which allows other areas to take over some functions. At the same time, muscle stiffness, contractures and bone deformities can progress as the child grows, which is why CP symptoms may seem to change even though the brain injury itself is stable.
For this reason, the goal of CP care is to maximize function, comfort, independence and participation, rather than to cure the condition.
What cell therapy may contribute
MSCs from Wharton's jelly do not become new neurons or replace damaged brain tissue. Research suggests they act through paracrine signaling, releasing factors that may:
- Modulate inflammation in the nervous system.
- Support surviving neurons and the formation of new connections.
- Promote blood vessel formation and tissue repair.
- Support neuroplasticity, which may make rehabilitation more effective.
These mechanisms are supported mostly by laboratory and animal studies. In humans, the question is whether they translate into meaningful functional improvement.
What the evidence shows
Randomized trial of IV umbilical cord MSCs
A randomized, double-blind, placebo-controlled trial published in Stem Cell Research & Therapy in 2020 studied 39 children aged 2 to 12 years with CP who received four IV infusions of umbilical cord MSCs or placebo, along with rehabilitation. Children in the MSC group showed greater improvement in gross motor function (GMFM), which became evident at 6 months and was maintained at 12 months, and greater improvement in activities of daily living. No serious adverse events were reported, and the most common side effects, such as temporary fever, occurred at similar rates in both groups.
Meta-analysis of randomized trials
A 2019 systematic review and meta-analysis in the World Journal of Stem Cells pooled data from randomized trials including 282 patients. Stem cell therapy was associated with a statistically significant improvement in gross motor function compared with standard care alone, with serious adverse events that were rare and similar between groups.
Cord blood studies
A randomized, placebo-controlled trial at Duke University, published in Stem Cells Translational Medicine in 2017, studied IV infusions of children's own banked cord blood. It highlighted that dose may matter: children who received higher doses showed greater motor improvement. This study used a different cell product, autologous cord blood, which is not used at Stem Cell Mexico, and its results should not be applied directly to Wharton's jelly MSCs.
What these studies mean
Taken together, the evidence suggests that some cell therapies may help children with CP gain improvements in motor function, particularly when combined with intensive rehabilitation. None of the studies showed a cure, normalization of movement or reversal of the brain injury. Results varied between participants.
Realistic improvements families may see
When improvements occur, they are usually gradual and specific. Examples reported in studies and by families include:
- Better head and trunk control, sitting balance or standing tolerance.
- Small gains in walking ability, endurance or hand use.
- Changes in muscle tone or spasticity.
- Improvements in attention, communication or engagement in therapy.
Because children with CP also develop and learn over time, especially with therapy, progress should be measured with standardized tools, such as the GMFM, before and after treatment.
Factors that influence outcomes
- Age: younger children may have more neuroplasticity, although adults with CP may also seek treatment for specific goals.
- Severity (GMFCS level): milder CP may allow more measurable functional gains.
- Type of CP: spastic, dyskinetic and ataxic forms behave differently.
- Associated conditions: uncontrolled epilepsy, nutrition problems and respiratory issues affect both safety and results.
- Rehabilitation: consistent physical, occupational and speech therapy is essential.
- Dose and route: studies differ in cell numbers, number of infusions and routes, which affects comparisons.
How Stem Cell Mexico approaches CP
- Cells: allogeneic MSCs from Wharton's jelly of donated umbilical cords, obtained after healthy, full-term births with informed consent and donor screening. No autologous cells, cord blood or other cell sources are used.
- Laboratory: produced in a COFEPRIS-licensed laboratory under Good Manufacturing Practice standards, with quality and safety testing before release.
- Evaluation: review of neurological reports, imaging, seizure history, GMFCS level, therapy reports and current medications.
- Treatment: usually IV infusion, with doses adjusted to body weight, under medical monitoring.
- Follow-up: coordinated with the family and the patient's therapists, with standardized assessments when possible.
A COFEPRIS license authorizes the facility and laboratory to operate.
Safety
Clinical studies show a generally reassuring short-term safety profile, with temporary fever, irritability, headache or fatigue as the most common effects. Safety depends on careful screening: seizure control, swallowing, breathing, nutrition and the need for sedation. No treatment is free of risk, and the medical team reviews each child's situation before treatment.
Standard care remains essential
The CDC emphasizes early, individualized intervention. Proven treatments include physical, occupational and speech therapy, medications for spasticity and seizures, botulinum toxin injections, orthotics, assistive devices and, when needed, orthopedic or neurosurgical procedures. Cell therapy, if chosen, is added to this care, never in place of it.
Warning signs
Be cautious if a clinic promises a cure, guarantees walking or speech, reports success rates without published data, says the treatment is risk-free or suggests stopping therapy or medications.
What our patients usually receive
Based on the treatment plans our team prepares for patients, a typical protocol at Stem Cell Mexico includes:
- Wharton's jelly MSCs by IV infusion, with the number of cells adjusted to body weight and confirmed after the doctor reviews the medical reports.
- One night at our facilities, sometimes two, with nursing and medical monitoring and a parent or caregiver present.
- Consultation with your doctor and the stem cell specialist, pre-treatment laboratory tests and ground transportation from the San Diego airport area.
- Complementary therapies, such as PRP, exosomes or NAD+, only when the doctor considers them useful; they are always listed in your written plan.
Recovery is gradual, and each person responds differently. Some patients begin noticing changes within the first weeks, while others notice them over the following months, which is why our team stays in contact after treatment to follow your progress and decide whether a second application could help.
Questions to ask during your evaluation
- What improvements are realistic for my child's type and severity of CP?
- How will progress be measured, and when?
- Which dose, route and number of applications are proposed, and why?
- How will seizures, sedation and feeding be managed during treatment?
- How will treatment be coordinated with current therapists?
Bottom line
Stem cell therapy does not cure cerebral palsy. Randomized studies suggest that umbilical cord MSCs may improve motor function and daily activities in some children when combined with rehabilitation, with a reassuring safety profile, and results vary between patients. At Stem Cell Mexico, Wharton's jelly MSCs are offered as a complement to therapy and medical care. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your child's or your own condition, goals and medical history.
References
- U.S. Centers for Disease Control and Prevention (CDC): Treatment and intervention for cerebral palsy (opens in a new tab)
- Gu J et al. Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial. Stem Cell Research & Therapy, 2020 (opens in a new tab)
- Eggenberger S et al. Stem cell treatment and cerebral palsy: systemic review and meta-analysis. World Journal of Stem Cells, 2019 (opens in a new tab)
- Sun JM et al. Effect of autologous cord blood infusion on motor function and brain connectivity in young children with cerebral palsy: a randomized, placebo-controlled trial. Stem Cells Translational Medicine, 2017 (opens in a new tab)
- International Society for Stem Cell Research (ISSCR): The ISSCR Guide to Stem Cell Treatments (opens in a new tab)
